arrow
A

Antonio Rullan

The Institute of Cancer Research
H指数:16
被引数:1,527

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy

系统给药的第二代STING激动剂与放疗联合促进抗肿瘤免疫的预临床疗效

2026-10-150
OAAI
Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion

组织特异性的成纤维细胞脂质信号影响上皮癌浸润速率

2026-04-270
OAAI
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

Xevinapant联合放化疗对头颈癌肿瘤免疫微环境的负面影响

2025-11-010
OA
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion

作者更正: Palbociclib和dsRNA传感器合作通过ER应激和调节免疫逃避来增强抗癌作用

2025-07-150
OAAI
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

PARP抑制剂talazoparib与呼肠孤病毒协同作用,在小鼠模型中体内诱导癌症杀伤和肿瘤控制

2025-07-080
OAAI
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
2025-05-250
OAAI
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models

靶向纤维细胞活化蛋白α的4-1BB激动剂与放射疗法协同作用以治疗小鼠乳腺癌模型

2025-02-111
OA
Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy
2024-08-130
OAAI